Quick Answer
Barinthus Biotherapeutics plc. reported Stockholders Equity of $74.21 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -42.9% in Stockholders Equity from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $254.40 million | Q3 2022: $243.84 million | Q1 2023: $233.30 million | Q2 2023: $217.21 million | Q3 2023: $195.40 million | Q1 2024: $171.83 million | Q2 2024: $156.62 million | Q3 2024: $159.29 million | Q1 2025: $115.49 million | Q2 2025: $102.38 million | Q3 2025: $84.47 million.
- Over the full 5 years of available data (2021 to 2025), Barinthus Biotherapeutics plc.'s Stockholders Equity has declined by 70.6%.
- Historical annual values: Fiscal year 2025: $74.21 million | Fiscal year 2024: $130.03 million | Fiscal year 2023: $186.78 million | Fiscal year 2022: $242.90 million | Fiscal year 2021: $252.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: